Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

28.000
+0.5001.82%
Volume:5.98M
Turnover:166.38M
Market Cap:24.42B
PE:80.88
High:28.400
Open:28.000
Low:27.100
Close:27.500
Loading ...

Hutchmed's Profit Falls in 2024

MT Newswires Live
·
20 Mar

Intended Retirement of Independent Non-Executive Directors and Changes of Composition of Board Committees

THOMSON REUTERS
·
20 Mar

HUTCHMED (China) Ltd - Savannah Phase Ii Trial Shows High Response Rates With Savolitinib Plus Tagrisso

THOMSON REUTERS
·
20 Mar

- HUTCHMED China Ltd - HUTCHMED Highlights Savolitinib Savannah Phase Ii

THOMSON REUTERS
·
20 Mar

BUZZ-HK-listed HUTCHMED jumps on 2024 profit beat

Reuters
·
20 Mar

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Benzinga
·
20 Mar

BRIEF-Hutchmed (China) Reports FY Net Income $ 37.7 Million

Reuters
·
19 Mar

Hutchmed's 2024 Earnings, Revenue Fall

MT Newswires Live
·
19 Mar

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

Benzinga
·
19 Mar

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

Benzinga
·
19 Mar

HUTCHMED (China) Ltd: 2025 Outlook Oncology/Immunology Consolidated Revenue $350 Mln-$450 Mln

THOMSON REUTERS
·
19 Mar

HUTCHMED China Ltd - 2024 Final Results and Business Updates

THOMSON REUTERS
·
19 Mar

HUTCHMED (China) FY Net Income USD 37.7 Million

THOMSON REUTERS
·
19 Mar

Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study

MT Newswires Live
·
19 Mar

Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint

Reuters
·
19 Mar

HUTCHMED (China) FY Revenue USD 203 Million VS. Ibes Estimate USD 673.5 Million

THOMSON REUTERS
·
13 Mar

Hutchmed (China) Completes Enrolment for Bile Duct Cancer Drug Trial

MT Newswires Live
·
07 Mar

Hutchmed Completes Enrollment for Phase 2 Primary Bile Duct Cancer Study

MT Newswires Live
·
06 Mar

HUTCHMED Announces That It Has Completed Enrollment of a Phase Ii Registration Study of Fanregratinib (Hmpl-453) for Intrahepatic Cholangiocarcinoma in China

THOMSON REUTERS
·
06 Mar

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire
·
05 Mar